1. Home
  2. SKLZ vs IFRX Comparison

SKLZ vs IFRX Comparison

Compare SKLZ & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skillz Inc.

SKLZ

Skillz Inc.

HOLD

Current Price

$2.87

Market Cap

57.3M

Sector

Technology

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$0.94

Market Cap

60.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKLZ
IFRX
Founded
2012
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
57.3M
60.6M
IPO Year
2020
2017

Fundamental Metrics

Financial Performance
Metric
SKLZ
IFRX
Price
$2.87
$0.94
Analyst Decision
Buy
Strong Buy
Analyst Count
1
6
Target Price
$14.00
$8.50
AVG Volume (30 Days)
34.6K
242.8K
Earning Date
05-07-2026
03-19-2026
Dividend Yield
N/A
N/A
EPS Growth
45.98
N/A
EPS
N/A
N/A
Revenue
$92,865,000.00
N/A
Revenue This Year
$13.33
N/A
Revenue Next Year
$12.68
$1,054.36
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.10
$0.71
52 Week High
$9.11
$1.94

Technical Indicators

Market Signals
Indicator
SKLZ
IFRX
Relative Strength Index (RSI) 36.99 55.39
Support Level N/A $0.96
Resistance Level $3.68 $1.16
Average True Range (ATR) 0.18 0.08
MACD -0.01 0.00
Stochastic Oscillator 0.00 68.30

Price Performance

Historical Comparison
SKLZ
IFRX

About SKLZ Skillz Inc.

Skillz Inc is a two-sided mobile gaming platform that connects developers with competitive players. The company's reportable business segments are: the Skillz segment and the Aarki segment. Skillz segment's highlights include Monetize Through Competitions, Player Matching, Cross-Platform Support, Comprehensive Analytics, and Focus on Game Development. Aarki is an artificial intelligence company that delivers advertising solutions. Some of the games available on its platform are Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube among others. The majority of its revenue is generated from the Skillz segment. Geographically, the company derives its key revenue from the United States and the rest from Israel, China, Malta, and other countries.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: